# OnCo record waldenstrom (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/waldenstrom/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "waldenstrom" ;
  schema:name "Waldenström macroglobulinaemia"@en ;
  schema:alternateName "Lymphoplasmacytic lymphoma"@en, "WM"@en, "LPL"@en, "Non-IgM lymphoplasmacytic lymphoma"@en, "IgM lymphoplasmacytic lymphoma"@en, "Waldenstrom macroglobulinemia"@en, "C88.0"@en ;
  schema:description "A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."@en ;
  schema:url <https://onco.cc/cancers/waldenstrom/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Waldenstr%C3%B6m_macroglobulinemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1778287> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475>, <https://iwmf.com/>, <https://doi.org/10.1182/blood.2020006844>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/active-monitoring-watch-and-wait>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/emotional-impact-living-lymphoma>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/terms/myd88-l265p/>, <https://onco.cc/biomarkers/btk-c481s/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/clonality-testing/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cxcr4/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/myd88/>, <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/mavorixafor/> ;
  onco:companies <https://onco.cc/companies/beone/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/ighv-status/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/myd88-l265p/>, <https://onco.cc/terms/m-protein-free-light-chains/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-watch-and-wait/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-indolent-lymphoma/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/lymphoma-bio-lymphgen/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/> ;
  onco:trials <https://onco.cc/trials/aspen-wm/> ;
  onco:people <https://onco.cc/people/meletios-dimopoulos/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tam-blood/> ;
  onco:pipeline <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/zanubrutinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/key-papers/paper-treon-blood/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/trials/aspen-wm/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/key-papers/paper-tam-blood/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/> .